Chronic myelogenous leukemia

Susan O'Brien, Ellin Berman, Hossein Borghaei, Daniel J. DeAngelo, Marcel P. Devetten, Steven Devine, Harry P. Erba, Jason Gotlib, Madan Jagasia, Joseph O. Moore, Tariq Mughal, Javier Pinilla-Ibarz, Jerald P. Radich, Neil P. Shah, Paul J. Shami, B. Douglas Smith, David S. Snyder, Martin S. Tallman, Moshe Talpaz, Meir Wetzler

Research output: Contribution to journalReview article

55 Scopus citations

Abstract

CML is a hematopoietic stem cell disease characterized by the presence of Ph chromosome resulting from the translocation between chromosomes 9 and 22 [t(9;22)].

Original languageEnglish (US)
Pages (from-to)984-1023
Number of pages40
JournalJNCCN Journal of the National Comprehensive Cancer Network
Volume7
Issue number9
DOIs
StatePublished - Oct 2009

    Fingerprint

Keywords

  • Allogenic HSCT
  • Chronic myelogenous leukemia
  • Cytogenetic response
  • Dasatinib
  • Hematologic response
  • Imatinib
  • Karyotyping
  • NCCN Clinical Practice Guidelines
  • Nilotinib
  • Transplantation

ASJC Scopus subject areas

  • Oncology

Cite this

O'Brien, S., Berman, E., Borghaei, H., DeAngelo, D. J., Devetten, M. P., Devine, S., Erba, H. P., Gotlib, J., Jagasia, M., Moore, J. O., Mughal, T., Pinilla-Ibarz, J., Radich, J. P., Shah, N. P., Shami, P. J., Smith, B. D., Snyder, D. S., Tallman, M. S., Talpaz, M., & Wetzler, M. (2009). Chronic myelogenous leukemia. JNCCN Journal of the National Comprehensive Cancer Network, 7(9), 984-1023. https://doi.org/10.6004/jnccn.2009.0065